nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftibuten—Body temperature increased—Chlorambucil—testicular cancer	0.0036	0.0036	CcSEcCtD
Ceftibuten—Abdominal pain—Chlorambucil—testicular cancer	0.0036	0.0036	CcSEcCtD
Ceftibuten—Constipation—Vinblastine—testicular cancer	0.00357	0.00357	CcSEcCtD
Ceftibuten—Candida infection—Epirubicin—testicular cancer	0.00357	0.00357	CcSEcCtD
Ceftibuten—Vaginal infection—Epirubicin—testicular cancer	0.00353	0.00353	CcSEcCtD
Ceftibuten—Anaphylactic shock—Bleomycin—testicular cancer	0.00352	0.00352	CcSEcCtD
Ceftibuten—Aplastic anaemia—Epirubicin—testicular cancer	0.00351	0.00351	CcSEcCtD
Ceftibuten—Agranulocytosis—Etoposide—testicular cancer	0.00348	0.00348	CcSEcCtD
Ceftibuten—Vaginal inflammation—Doxorubicin—testicular cancer	0.00346	0.00346	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Vinblastine—testicular cancer	0.00341	0.00341	CcSEcCtD
Ceftibuten—Eructation—Doxorubicin—testicular cancer	0.0034	0.0034	CcSEcCtD
Ceftibuten—Agitation—Ifosfamide—testicular cancer	0.00339	0.00339	CcSEcCtD
Ceftibuten—Melaena—Doxorubicin—testicular cancer	0.00338	0.00338	CcSEcCtD
Ceftibuten—Anorexia—Bleomycin—testicular cancer	0.00336	0.00336	CcSEcCtD
Ceftibuten—Hypersensitivity—Chlorambucil—testicular cancer	0.00335	0.00335	CcSEcCtD
Ceftibuten—Candida infection—Doxorubicin—testicular cancer	0.0033	0.0033	CcSEcCtD
Ceftibuten—Abdominal pain—Vinblastine—testicular cancer	0.0033	0.0033	CcSEcCtD
Ceftibuten—Asthenia—Chlorambucil—testicular cancer	0.00326	0.00326	CcSEcCtD
Ceftibuten—Vaginal infection—Doxorubicin—testicular cancer	0.00326	0.00326	CcSEcCtD
Ceftibuten—Aplastic anaemia—Doxorubicin—testicular cancer	0.00324	0.00324	CcSEcCtD
Ceftibuten—Pruritus—Chlorambucil—testicular cancer	0.00322	0.00322	CcSEcCtD
Ceftibuten—Convulsion—Ifosfamide—testicular cancer	0.0032	0.0032	CcSEcCtD
Ceftibuten—Erythema multiforme—Etoposide—testicular cancer	0.00316	0.00316	CcSEcCtD
Ceftibuten—Paraesthesia—Bleomycin—testicular cancer	0.00316	0.00316	CcSEcCtD
Ceftibuten—Dyspnoea—Bleomycin—testicular cancer	0.00314	0.00314	CcSEcCtD
Ceftibuten—Flatulence—Cisplatin—testicular cancer	0.00313	0.00313	CcSEcCtD
Ceftibuten—Anorexia—Dactinomycin—testicular cancer	0.00313	0.00313	CcSEcCtD
Ceftibuten—Diarrhoea—Chlorambucil—testicular cancer	0.00311	0.00311	CcSEcCtD
Ceftibuten—Hypersensitivity—Vinblastine—testicular cancer	0.00307	0.00307	CcSEcCtD
Ceftibuten—Decreased appetite—Bleomycin—testicular cancer	0.00306	0.00306	CcSEcCtD
Ceftibuten—Anaphylactic shock—Ifosfamide—testicular cancer	0.00301	0.00301	CcSEcCtD
Ceftibuten—Chills—Etoposide—testicular cancer	0.003	0.003	CcSEcCtD
Ceftibuten—Asthenia—Vinblastine—testicular cancer	0.00299	0.00299	CcSEcCtD
Ceftibuten—Vomiting—Chlorambucil—testicular cancer	0.00289	0.00289	CcSEcCtD
Ceftibuten—Anorexia—Ifosfamide—testicular cancer	0.00287	0.00287	CcSEcCtD
Ceftibuten—Decreased appetite—Dactinomycin—testicular cancer	0.00286	0.00286	CcSEcCtD
Ceftibuten—Diarrhoea—Vinblastine—testicular cancer	0.00285	0.00285	CcSEcCtD
Ceftibuten—Dysgeusia—Etoposide—testicular cancer	0.00285	0.00285	CcSEcCtD
Ceftibuten—Renal impairment—Epirubicin—testicular cancer	0.00285	0.00285	CcSEcCtD
Ceftibuten—Fatigue—Dactinomycin—testicular cancer	0.00283	0.00283	CcSEcCtD
Ceftibuten—Urticaria—Bleomycin—testicular cancer	0.0028	0.0028	CcSEcCtD
Ceftibuten—Body temperature increased—Bleomycin—testicular cancer	0.00278	0.00278	CcSEcCtD
Ceftibuten—Irritability—Methotrexate—testicular cancer	0.00277	0.00277	CcSEcCtD
Ceftibuten—Dizziness—Vinblastine—testicular cancer	0.00276	0.00276	CcSEcCtD
Ceftibuten—Convulsion—Cisplatin—testicular cancer	0.00275	0.00275	CcSEcCtD
Ceftibuten—Nausea—Chlorambucil—testicular cancer	0.0027	0.0027	CcSEcCtD
Ceftibuten—Paraesthesia—Ifosfamide—testicular cancer	0.0027	0.0027	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00269	0.00269	CcSEcCtD
Ceftibuten—Dyspnoea—Ifosfamide—testicular cancer	0.00268	0.00268	CcSEcCtD
Ceftibuten—Somnolence—Ifosfamide—testicular cancer	0.00268	0.00268	CcSEcCtD
Ceftibuten—Vomiting—Vinblastine—testicular cancer	0.00265	0.00265	CcSEcCtD
Ceftibuten—Renal impairment—Doxorubicin—testicular cancer	0.00264	0.00264	CcSEcCtD
Ceftibuten—Decreased appetite—Ifosfamide—testicular cancer	0.00262	0.00262	CcSEcCtD
Ceftibuten—Headache—Vinblastine—testicular cancer	0.00261	0.00261	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.00261	0.00261	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.0026	0.0026	CcSEcCtD
Ceftibuten—Abdominal pain—Dactinomycin—testicular cancer	0.0026	0.0026	CcSEcCtD
Ceftibuten—Body temperature increased—Dactinomycin—testicular cancer	0.0026	0.0026	CcSEcCtD
Ceftibuten—Fatigue—Ifosfamide—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftibuten—Anaphylactic shock—Cisplatin—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftibuten—Hypersensitivity—Bleomycin—testicular cancer	0.00259	0.00259	CcSEcCtD
Ceftibuten—Constipation—Ifosfamide—testicular cancer	0.00257	0.00257	CcSEcCtD
Ceftibuten—Asthenia—Bleomycin—testicular cancer	0.00253	0.00253	CcSEcCtD
Ceftibuten—Convulsion—Etoposide—testicular cancer	0.00252	0.00252	CcSEcCtD
Ceftibuten—Dehydration—Epirubicin—testicular cancer	0.00252	0.00252	CcSEcCtD
Ceftibuten—Pruritus—Bleomycin—testicular cancer	0.00249	0.00249	CcSEcCtD
Ceftibuten—Nausea—Vinblastine—testicular cancer	0.00248	0.00248	CcSEcCtD
Ceftibuten—Anorexia—Cisplatin—testicular cancer	0.00247	0.00247	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00246	0.00246	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00244	0.00244	CcSEcCtD
Ceftibuten—Hypersensitivity—Dactinomycin—testicular cancer	0.00242	0.00242	CcSEcCtD
Ceftibuten—Urticaria—Ifosfamide—testicular cancer	0.00239	0.00239	CcSEcCtD
Ceftibuten—Body temperature increased—Ifosfamide—testicular cancer	0.00238	0.00238	CcSEcCtD
Ceftibuten—Abdominal pain—Ifosfamide—testicular cancer	0.00238	0.00238	CcSEcCtD
Ceftibuten—Pancytopenia—Methotrexate—testicular cancer	0.00238	0.00238	CcSEcCtD
Ceftibuten—Anaphylactic shock—Etoposide—testicular cancer	0.00238	0.00238	CcSEcCtD
Ceftibuten—Asthenia—Dactinomycin—testicular cancer	0.00236	0.00236	CcSEcCtD
Ceftibuten—Dysuria—Methotrexate—testicular cancer	0.00234	0.00234	CcSEcCtD
Ceftibuten—Neutropenia—Methotrexate—testicular cancer	0.00234	0.00234	CcSEcCtD
Ceftibuten—Dehydration—Doxorubicin—testicular cancer	0.00233	0.00233	CcSEcCtD
Ceftibuten—Paraesthesia—Cisplatin—testicular cancer	0.00233	0.00233	CcSEcCtD
Ceftibuten—Dyspnoea—Cisplatin—testicular cancer	0.00231	0.00231	CcSEcCtD
Ceftibuten—Anorexia—Etoposide—testicular cancer	0.00227	0.00227	CcSEcCtD
Ceftibuten—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00226	0.00226	CcSEcCtD
Ceftibuten—Decreased appetite—Cisplatin—testicular cancer	0.00226	0.00226	CcSEcCtD
Ceftibuten—Diarrhoea—Dactinomycin—testicular cancer	0.00225	0.00225	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00224	0.00224	CcSEcCtD
Ceftibuten—Vomiting—Bleomycin—testicular cancer	0.00224	0.00224	CcSEcCtD
Ceftibuten—Pancytopenia—Epirubicin—testicular cancer	0.00223	0.00223	CcSEcCtD
Ceftibuten—Rash—Bleomycin—testicular cancer	0.00222	0.00222	CcSEcCtD
Ceftibuten—Dermatitis—Bleomycin—testicular cancer	0.00222	0.00222	CcSEcCtD
Ceftibuten—Hypersensitivity—Ifosfamide—testicular cancer	0.00222	0.00222	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00221	0.00221	CcSEcCtD
Ceftibuten—Renal failure—Methotrexate—testicular cancer	0.00219	0.00219	CcSEcCtD
Ceftibuten—Dysuria—Epirubicin—testicular cancer	0.00219	0.00219	CcSEcCtD
Ceftibuten—Neutropenia—Epirubicin—testicular cancer	0.00219	0.00219	CcSEcCtD
Ceftibuten—Asthenia—Ifosfamide—testicular cancer	0.00216	0.00216	CcSEcCtD
Ceftibuten—Paraesthesia—Etoposide—testicular cancer	0.00213	0.00213	CcSEcCtD
Ceftibuten—Pruritus—Ifosfamide—testicular cancer	0.00213	0.00213	CcSEcCtD
Ceftibuten—Haematuria—Methotrexate—testicular cancer	0.00213	0.00213	CcSEcCtD
Ceftibuten—Dyspnoea—Etoposide—testicular cancer	0.00212	0.00212	CcSEcCtD
Ceftibuten—Somnolence—Etoposide—testicular cancer	0.00211	0.00211	CcSEcCtD
Ceftibuten—Nausea—Bleomycin—testicular cancer	0.00209	0.00209	CcSEcCtD
Ceftibuten—Vomiting—Dactinomycin—testicular cancer	0.00209	0.00209	CcSEcCtD
Ceftibuten—Agranulocytosis—Methotrexate—testicular cancer	0.00208	0.00208	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00207	0.00207	CcSEcCtD
Ceftibuten—Rash—Dactinomycin—testicular cancer	0.00207	0.00207	CcSEcCtD
Ceftibuten—Decreased appetite—Etoposide—testicular cancer	0.00207	0.00207	CcSEcCtD
Ceftibuten—Diarrhoea—Ifosfamide—testicular cancer	0.00206	0.00206	CcSEcCtD
Ceftibuten—Pancytopenia—Doxorubicin—testicular cancer	0.00206	0.00206	CcSEcCtD
Ceftibuten—Renal failure—Epirubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Etoposide—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftibuten—Body temperature increased—Cisplatin—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftibuten—Fatigue—Etoposide—testicular cancer	0.00205	0.00205	CcSEcCtD
Ceftibuten—Jaundice—Epirubicin—testicular cancer	0.00204	0.00204	CcSEcCtD
Ceftibuten—Constipation—Etoposide—testicular cancer	0.00203	0.00203	CcSEcCtD
Ceftibuten—Dysuria—Doxorubicin—testicular cancer	0.00203	0.00203	CcSEcCtD
Ceftibuten—Neutropenia—Doxorubicin—testicular cancer	0.00203	0.00203	CcSEcCtD
Ceftibuten—Haemoglobin—Methotrexate—testicular cancer	0.00201	0.00201	CcSEcCtD
Ceftibuten—Haemorrhage—Methotrexate—testicular cancer	0.002	0.002	CcSEcCtD
Ceftibuten—Haematuria—Epirubicin—testicular cancer	0.00199	0.00199	CcSEcCtD
Ceftibuten—Dizziness—Ifosfamide—testicular cancer	0.00199	0.00199	CcSEcCtD
Ceftibuten—Nausea—Dactinomycin—testicular cancer	0.00195	0.00195	CcSEcCtD
Ceftibuten—Agranulocytosis—Epirubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Etoposide—testicular cancer	0.00194	0.00194	CcSEcCtD
Ceftibuten—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00192	0.00192	CcSEcCtD
Ceftibuten—Vomiting—Ifosfamide—testicular cancer	0.00191	0.00191	CcSEcCtD
Ceftibuten—Hypersensitivity—Cisplatin—testicular cancer	0.00191	0.00191	CcSEcCtD
Ceftibuten—Renal failure—Doxorubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Ceftibuten—Rash—Ifosfamide—testicular cancer	0.0019	0.0019	CcSEcCtD
Ceftibuten—Dermatitis—Ifosfamide—testicular cancer	0.0019	0.0019	CcSEcCtD
Ceftibuten—Erythema multiforme—Methotrexate—testicular cancer	0.0019	0.0019	CcSEcCtD
Ceftibuten—Urticaria—Etoposide—testicular cancer	0.00189	0.00189	CcSEcCtD
Ceftibuten—Haemoglobin—Epirubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Ceftibuten—Jaundice—Doxorubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Ceftibuten—Body temperature increased—Etoposide—testicular cancer	0.00188	0.00188	CcSEcCtD
Ceftibuten—Abdominal pain—Etoposide—testicular cancer	0.00188	0.00188	CcSEcCtD
Ceftibuten—Haemorrhage—Epirubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Ceftibuten—Asthenia—Cisplatin—testicular cancer	0.00186	0.00186	CcSEcCtD
Ceftibuten—Haematuria—Doxorubicin—testicular cancer	0.00184	0.00184	CcSEcCtD
Ceftibuten—Agranulocytosis—Doxorubicin—testicular cancer	0.0018	0.0018	CcSEcCtD
Ceftibuten—Chills—Methotrexate—testicular cancer	0.0018	0.0018	CcSEcCtD
Ceftibuten—Nausea—Ifosfamide—testicular cancer	0.00179	0.00179	CcSEcCtD
Ceftibuten—Diarrhoea—Cisplatin—testicular cancer	0.00178	0.00178	CcSEcCtD
Ceftibuten—Erythema multiforme—Epirubicin—testicular cancer	0.00177	0.00177	CcSEcCtD
Ceftibuten—Hypersensitivity—Etoposide—testicular cancer	0.00175	0.00175	CcSEcCtD
Ceftibuten—Haemoglobin—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Ceftibuten—Haemorrhage—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Ceftibuten—Dysgeusia—Methotrexate—testicular cancer	0.00171	0.00171	CcSEcCtD
Ceftibuten—Asthenia—Etoposide—testicular cancer	0.00171	0.00171	CcSEcCtD
Ceftibuten—Chills—Epirubicin—testicular cancer	0.00168	0.00168	CcSEcCtD
Ceftibuten—Pruritus—Etoposide—testicular cancer	0.00168	0.00168	CcSEcCtD
Ceftibuten—Vomiting—Cisplatin—testicular cancer	0.00165	0.00165	CcSEcCtD
Ceftibuten—Erythema multiforme—Doxorubicin—testicular cancer	0.00164	0.00164	CcSEcCtD
Ceftibuten—Rash—Cisplatin—testicular cancer	0.00164	0.00164	CcSEcCtD
Ceftibuten—Dermatitis—Cisplatin—testicular cancer	0.00163	0.00163	CcSEcCtD
Ceftibuten—Diarrhoea—Etoposide—testicular cancer	0.00163	0.00163	CcSEcCtD
Ceftibuten—Flatulence—Epirubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Ceftibuten—Dysgeusia—Epirubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Ceftibuten—Dizziness—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Ceftibuten—Chills—Doxorubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Ceftibuten—Nausea—Cisplatin—testicular cancer	0.00154	0.00154	CcSEcCtD
Ceftibuten—Convulsion—Methotrexate—testicular cancer	0.00151	0.00151	CcSEcCtD
Ceftibuten—Vomiting—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Ceftibuten—Agitation—Epirubicin—testicular cancer	0.0015	0.0015	CcSEcCtD
Ceftibuten—Rash—Etoposide—testicular cancer	0.0015	0.0015	CcSEcCtD
Ceftibuten—Dermatitis—Etoposide—testicular cancer	0.0015	0.0015	CcSEcCtD
Ceftibuten—Headache—Etoposide—testicular cancer	0.00149	0.00149	CcSEcCtD
Ceftibuten—Flatulence—Doxorubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Ceftibuten—Dysgeusia—Doxorubicin—testicular cancer	0.00148	0.00148	CcSEcCtD
Ceftibuten—Anaphylactic shock—Methotrexate—testicular cancer	0.00142	0.00142	CcSEcCtD
Ceftibuten—Convulsion—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Ceftibuten—Nausea—Etoposide—testicular cancer	0.00141	0.00141	CcSEcCtD
Ceftibuten—Agitation—Doxorubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Ceftibuten—Dry mouth—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Ceftibuten—Anorexia—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Ceftibuten—Anaphylactic shock—Epirubicin—testicular cancer	0.00133	0.00133	CcSEcCtD
Ceftibuten—Convulsion—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Ceftibuten—Insomnia—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Ceftibuten—Paraesthesia—Methotrexate—testicular cancer	0.00128	0.00128	CcSEcCtD
Ceftibuten—Anorexia—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Ceftibuten—Dyspnoea—Methotrexate—testicular cancer	0.00127	0.00127	CcSEcCtD
Ceftibuten—Somnolence—Methotrexate—testicular cancer	0.00127	0.00127	CcSEcCtD
Ceftibuten—Dry mouth—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Ceftibuten—Dyspepsia—Methotrexate—testicular cancer	0.00125	0.00125	CcSEcCtD
Ceftibuten—Decreased appetite—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Ceftibuten—Anaphylactic shock—Doxorubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00123	0.00123	CcSEcCtD
Ceftibuten—Fatigue—Methotrexate—testicular cancer	0.00123	0.00123	CcSEcCtD
Ceftibuten—Insomnia—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Ceftibuten—Paraesthesia—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Ceftibuten—Dyspnoea—Epirubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Ceftibuten—Somnolence—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Ceftibuten—Anorexia—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Ceftibuten—Dyspepsia—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Ceftibuten—Decreased appetite—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Ceftibuten—Fatigue—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Ceftibuten—Constipation—Epirubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Ceftibuten—Urticaria—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Ceftibuten—Body temperature increased—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Ceftibuten—Abdominal pain—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Ceftibuten—Insomnia—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Ceftibuten—Paraesthesia—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Ceftibuten—Dyspnoea—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Ceftibuten—Somnolence—Doxorubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Ceftibuten—Dyspepsia—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Ceftibuten—Decreased appetite—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Ceftibuten—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Ceftibuten—Fatigue—Doxorubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Ceftibuten—Urticaria—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Ceftibuten—Constipation—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftibuten—Abdominal pain—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftibuten—Body temperature increased—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftibuten—Hypersensitivity—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Ceftibuten—Asthenia—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Ceftibuten—Gastrointestinal pain—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Ceftibuten—Pruritus—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Ceftibuten—Hypersensitivity—Epirubicin—testicular cancer	0.000982	0.000982	CcSEcCtD
Ceftibuten—Urticaria—Doxorubicin—testicular cancer	0.000979	0.000979	CcSEcCtD
Ceftibuten—Abdominal pain—Doxorubicin—testicular cancer	0.000975	0.000975	CcSEcCtD
Ceftibuten—Body temperature increased—Doxorubicin—testicular cancer	0.000975	0.000975	CcSEcCtD
Ceftibuten—Diarrhoea—Methotrexate—testicular cancer	0.000974	0.000974	CcSEcCtD
Ceftibuten—Asthenia—Epirubicin—testicular cancer	0.000956	0.000956	CcSEcCtD
Ceftibuten—Pruritus—Epirubicin—testicular cancer	0.000943	0.000943	CcSEcCtD
Ceftibuten—Dizziness—Methotrexate—testicular cancer	0.000942	0.000942	CcSEcCtD
Ceftibuten—Diarrhoea—Epirubicin—testicular cancer	0.000912	0.000912	CcSEcCtD
Ceftibuten—Hypersensitivity—Doxorubicin—testicular cancer	0.000908	0.000908	CcSEcCtD
Ceftibuten—Vomiting—Methotrexate—testicular cancer	0.000905	0.000905	CcSEcCtD
Ceftibuten—Rash—Methotrexate—testicular cancer	0.000898	0.000898	CcSEcCtD
Ceftibuten—Dermatitis—Methotrexate—testicular cancer	0.000897	0.000897	CcSEcCtD
Ceftibuten—Headache—Methotrexate—testicular cancer	0.000892	0.000892	CcSEcCtD
Ceftibuten—Asthenia—Doxorubicin—testicular cancer	0.000885	0.000885	CcSEcCtD
Ceftibuten—Dizziness—Epirubicin—testicular cancer	0.000881	0.000881	CcSEcCtD
Ceftibuten—Pruritus—Doxorubicin—testicular cancer	0.000872	0.000872	CcSEcCtD
Ceftibuten—Vomiting—Epirubicin—testicular cancer	0.000847	0.000847	CcSEcCtD
Ceftibuten—Nausea—Methotrexate—testicular cancer	0.000846	0.000846	CcSEcCtD
Ceftibuten—Diarrhoea—Doxorubicin—testicular cancer	0.000844	0.000844	CcSEcCtD
Ceftibuten—Rash—Epirubicin—testicular cancer	0.00084	0.00084	CcSEcCtD
Ceftibuten—Dermatitis—Epirubicin—testicular cancer	0.000839	0.000839	CcSEcCtD
Ceftibuten—Headache—Epirubicin—testicular cancer	0.000835	0.000835	CcSEcCtD
Ceftibuten—Dizziness—Doxorubicin—testicular cancer	0.000815	0.000815	CcSEcCtD
Ceftibuten—Nausea—Epirubicin—testicular cancer	0.000792	0.000792	CcSEcCtD
Ceftibuten—Vomiting—Doxorubicin—testicular cancer	0.000784	0.000784	CcSEcCtD
Ceftibuten—Rash—Doxorubicin—testicular cancer	0.000777	0.000777	CcSEcCtD
Ceftibuten—Dermatitis—Doxorubicin—testicular cancer	0.000777	0.000777	CcSEcCtD
Ceftibuten—Headache—Doxorubicin—testicular cancer	0.000772	0.000772	CcSEcCtD
Ceftibuten—Nausea—Doxorubicin—testicular cancer	0.000732	0.000732	CcSEcCtD
